HC Deb 19 January 1998 vol 304 c389W
Mrs. Dunwoody

To ask the Secretary of State for Health what cost benefit analysis has been conducted into the privatisation of travel vaccinations for infectious diseases. [22906]

Ms Jowell

The non-availability or unreliability of data on travel vaccines given in the United Kingdom makes formal cost-benefit analysis difficult. We recognise that inconsistencies and ambiguities have arisen over the years in the arrangements for travel vaccines and the way they are interpreted and are seeking to resolve these anomalies as part of an ongoing, internal review.